Anwaar Saeed

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · The Lancet Oncology · 2022 · 222 citations

Medicine, Oncology, Pharmacotherapy +14

T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma

Maryam Barsch, Henrike Salié, Alexandra Emilia Schlaak et al. · Journal of Hepatology · 2022 · 187 citations

Medicine, Cancer Biology, Oncology +17

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 152 citations · Full text

Medicine, Immunology, Oncology +17

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio et al. · European Journal of Cancer · 2022 · 112 citations · Full text

Medicine, Oncology, Pharmacology +6